A 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2018
At a glance
- Drugs Ichorcumab (Primary) ; Ichorcumab (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 13 Jul 2018 Status changed from recruiting to completed.
- 11 Apr 2018 Planned End Date changed from 23 Jul 2018 to 16 Jun 2018.
- 11 Apr 2018 Planned primary completion date changed from 23 Jun 2018 to 16 Jun 2018.